Hot Investor Mandate: Investment Firm With China Headquarters Invests Up to $8M in Therapeutics, Devices, and Diagnostics Companies

22 Jan

An investment firm headquartered in China with offices in the US, is focused on early-stage investments in life science and healthcare sectors. The firm typically engages in pre-A to series B financing rounds, with initial investment sizes ranges from $500k to $8M, and potential for follow-on investments. The firm looks for opportunities mostly in Europe, and in the US and UK as well. The firm is open to both leading and co-investing.

The firm is interested in therapeutics, medical devices and diagnostics. The firm is open to looking at digital health, AI -related companies but has not invested in one yet. The firm is opportunistic in terms of subsectors and indications. Some areas of interest include immunology, immuno-oncology, CNS disorders and kidney-related diseases. For therapeutics, the firm is open to looking at companies from phase I to beyond, particularly those with proof of concepts or clinical data validating their technologies. For medical devices and diagnostics, the firm tends to look for more mature companies, with product or prototype ready and as well as plans for regulatory approvals.

The firm does not have specific requirements for a company’s management team but prefers to work with founding teams that have entrepreneurial experiences previously.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment